Volume | 21 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ESSA Pharma Inc | EPIX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.90 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
5 | 21 | - | 2.58 - 11.67 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
08:13:54 | 6 | $ 5.05 | USD |
ESSA Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
216.77M | 44.24M | - | 0 | -26.58M | -0.60 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ESSA Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EPIX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.33 | 5.828 | 4.59 | 4.96 | 91,547 | -0.43 | -8.07% |
1 Month | 6.22 | 6.85 | 4.59 | 5.71 | 69,494 | -1.32 | -21.22% |
3 Months | 9.08 | 9.23 | 4.59 | 6.55 | 62,743 | -4.18 | -46.04% |
6 Months | 6.24 | 11.67 | 4.59 | 8.34 | 109,922 | -1.34 | -21.47% |
1 Year | 3.14 | 11.67 | 2.58 | 6.21 | 110,909 | 1.76 | 56.05% |
3 Years | 27.06 | 30.2599 | 1.40 | 5.86 | 480,257 | -22.16 | -81.89% |
5 Years | 2.30 | 36.00 | 1.40 | 7.62 | 335,913 | 2.60 | 113.04% |
ESSA Pharma Description
ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. |